胸主动脉-股动脉旁路术作为近肾段腹主动脉完全闭塞初始治疗的长期结果
回顾性分析2005至2021年31例因严重主髂动脉闭塞性疾病首次接受胸主动脉-股动脉旁路术的患者,其中严重跛行组21例、慢性肢体威胁性缺血组10例,平均随访79个月,5年原发通畅率96%±7%、继发通畅率96.3%±6%,30天死亡率为3.2%。
要点
- 31例近肾段腹主动脉完全闭塞患者首次行胸主动脉-股动脉旁路术,22例(83.8%)术后无症状。
- 30天死亡率为3.2%(n=1),主要并发症发生率9.6%(n=3)。
- 5年原发通畅率96%±7%(95%CI 88.6-100),继发通畅率96.3%±6%(95%CI 89.4-100)。
核心结论
- 在经选择的近肾段腹主动脉完全闭塞患者中,将胸主动脉-股动脉旁路术作为初始治疗可取得良好结果。
- 尽管胸主动脉-股动脉旁路术是复杂的外科技术,但在经选择的患者中显示出安全、可接受的死亡率和并发症率以及良好的长期随访结果。
研究设计与样本
- 回顾性分析2005年至2021年因严重主髂动脉闭塞性疾病首次接受胸主动脉-股动脉旁路术的31例连续患者,所有患者均具有肾水平腹主动脉闭塞和钙化斑块的共同特征。
- 患者分为严重跛行组(Rutherford III级)21例(67.7%)和慢性肢体威胁性缺血组(Rutherford IV-V级)10例(32.3%)。
- 分类变量组间比较采用卡方检验或Fisher精确检验,连续变量按分布采用t检验或Mann-Whitney U检验,采用Kaplan-Meier曲线描绘时间-事件数据。
主要发现
- 31例患者年龄62(56-67.5)岁,男性87%;平均随访79±32个月。
- 22例(83.8%)在胸主动脉-股动脉旁路术后保持无症状。
- 30天死亡率为3.2%(n=1);主要并发症发生率为9.6%(n=3;呼吸系统6.4%,腹膜后血肿3.2%)。
- 跛行组与慢性肢体威胁性缺血组的主要并发症发生率无显著差异(3.2% vs 6.4%,P=NS)。
- 轻微并发症发生率为41.9%,包括胸腔积液9.6%(n=3)、急性肾损伤9.6%(n=3)、胃肠道出血3.2%(n=1)、麻痹性肠梗阻6.4%(n=2)、浅表皮肤感染12.9%(n=4);慢性肢体威胁性缺血组术后浅表皮肤感染率高于跛行组(4例[40%] vs 0例[0%],P=0.007)。
临床怎么用
- 原文结论认为,在经选择的近肾段腹主动脉完全闭塞患者中,胸主动脉-股动脉旁路术作为初始治疗可取得良好结果,是一种安全、死亡率和并发症率可接受且长期随访结果良好的复杂外科技术。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Thoracofemoral bypass has been applied mostly secondary to previous procedures in the treatment of aortoiliac occlusive disease. However, its application as an initial treatment is less common, and long-term outcomes remain uncertain. The aim of this analysis was to review the 16-year experience and long-term outcomes of 31 consecutive patients who underwent thoracofemoral bypass as the primary procedure. METHODS: All patients who underwent thoracofemoral bypass for severe aortoiliac occlusive disease between 2005 and 2021 were retrospectively analyzed. The occlusion and calcified plaques of the abdominal aorta at the renal level were common characteristics of all patients. The patients were divided into 2 groups: severe claudication group (Rutherford III group) and chronic limb-threatening ischemia group (Rutherford IV-V). Chi-square test or Fisher's exact test was used to compare categorical variables between the groups, and t-test or Mann-Whitney U-tests were used to compare continuous variables according to their distributions. The Kaplan-Meier curve was used to depict the time-to-event data. RESULTS: Thirty-one patients [age: 62 (56-67.5); male: 87%] underwent thoracofemoral bypass. Among the 31 patients, 21 (67.7%) belonged to the severe claudication group (Rutherford III), while 10 (32.3%) were in the chronic limb-threatening ischemia (Rutherford IV-V). Twenty-two patients (83.8%) remained asymptomatic after thoracofemoral bypass. The mean follow-up duration was 79 ± 32 months. The 30-day mortality rate was 3.2% (n = 1). Major complications were observed in 9.6% of patients (n = 3; respiratory: 6.4%, retroperitoneal hematoma: 3.2%). No significant difference was found between the claudication and chronic limb-threatening ischemia groups regarding major complications (3.2% vs. 6.4%, P = NS). Minor complications occurred in 41.9% of patients, including pleural effusion 9.6% (n = 3), acute kidney injury 9.6% (n = 3), gastrointestinal bleeding 3.2% (n = 1), paralytic ileus 6.4% (n = 2), and superficial skin infection 12.9% (n = 4). The rate of postoperative superficial skin infection was higher in the chronic limb-threatening ischemia group compared to the claudication group (4 [40%] vs. 0 [0%], P: 0.007). The univariable Cox regression analysis revealed that hypertension and diabetes mellitus were not related to primary patency of the thoracofemoral bypass graft. The 5-year Kaplan-Meier estimated primary patency for the entire study was 96% ± 7% (95% confidence interval [CI]: 88.6-100), and the secondary patency was 96.3% ± 6% (95% CI: 89.4-100). The 5-year Kaplan-Meier estimated survival rate after thoracofemoral bypass was 93.4% ± 3 (95% CI: 91-100). CONCLUSIONS: We demonstrated in this study that thoracofemoral bypass can yield good outcomes when preferred as the initial treatment in selected patients with juxtarenal total aortic occlusion. Despite being a complex surgical technique, thoracofemoral bypass has shown to have safe, acceptable mortality and morbidity rates, as well as excellent long-term follow-up results in selected patients.
引用
- Sarikaya S, Altas O, Deniz G, et al. Long-Term Results of Thoracofemoral Bypass in the Initial Treatment of Juxtarenal Total Aortic Occlusion. Ann Vasc Surg. 2023. PMID: 37918658. doi:10.1016/j.avsg.2023.09.069
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。